Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven Income 1 Regulatory News (MIG1)

Share Price Information for Maven Income 1 (MIG1)

Share Price is delayed by 15 minutes
Get Live Data
33.80    0.00 (0.00%)
Bid:
32.80
Ask:
34.80
Spread: 2.00 (6.098%)
Market Cap: £70.05m
MIG1 Live PriceLast checked at - London Stock Exchange

Intraday Maven Income 1 Share Chart

Interim Management Statement

7 Jan 2009 15:54

RNS Number : 2807L
Aberdeen Income & Growth VCT PLC
07 January 2009
Β 

ο»Ώ

AberdeenΒ Income and GrowthΒ VCT PLCΒ (the Company)

Interim Management StatementΒ -Β Quarter ended 30Β NovemberΒ 2008

ThisΒ Interim Management Statement,Β for theΒ quarterΒ endedΒ 30Β NovemberΒ 2008, is provided in accordance with Rule 4.3 of the Disclosure and TransparencyΒ Rules of the UK Listing AuthorityΒ andΒ also includes relevant informationΒ in respect of the period from 1Β DecemberΒ 2008Β toΒ the date ofΒ issue.Β ThisΒ Statement has been prepared solely to provide additional informationΒ in orderΒ to meet the relevant requirements of the UK Listing Authority's Disclosure and Transparency Rules, and should not be relied on by Shareholders,Β or any other party,Β for any other purpose.

1.

Financial highlights

Net Asset Value (NAV)*Β ofΒ 68.6pΒ per shareΒ atΒ 30 NovemberΒ 2008Β compared toΒ 69.7p per share atΒ 31 AugustΒ 2008; and InterimΒ dividendΒ ofΒ 1.0p per shareΒ paidΒ onΒ 12Β DecemberΒ 2008.

*The NAVΒ is unaudited andΒ reflects theΒ closingΒ bid priceΒ of quoted securitiesΒ atΒ 30 NovemberΒ 2008. Unlisted companies areΒ normallyΒ valued on a six-monthly basis and the NAV incorporates the Directors'Β valuationΒ of unlistedΒ investmentsΒ asΒ atΒ 31 AugustΒ 2008, adjusted for subsequent events where appropriate.Β 

2.

InvestmentsΒ and disposals

During the quarter endedΒ 30 NovemberΒ 2008,Β investmentsΒ totallingΒ Β£141,000 were madeΒ inΒ oneΒ unlistedΒ andΒ  twoΒ AIM quoted companies and Β£729,000 was invested in listedΒ UKΒ government securities

DuringΒ theΒ same period, a combination of partial and complete disposals ofΒ one unlisted investment and fourΒ AIM quoted investments generated aggregate proceeds of Β£266,000 against cost of Β£203,000.Β 

Β 

There were no other material transactions during the period under review.Β 

3.

Recent developmentsΒ 

BetweenΒ 30 NovemberΒ 2008Β and the date of this statement,Β investments totallingΒ Β£115,000Β wereΒ made inΒ oneΒ  AIM quotedΒ companyΒ and one unlistedΒ company. DuringΒ the same post quarter-end period,Β disposalsΒ ofΒ a listedΒ UKΒ government security,Β oneΒ unlistedΒ investmentΒ andΒ twoΒ AIM quoted investmentsΒ generatedΒ aggregateΒ  proceeds of Β£658,000Β against cost of Β£674,000.

Other than described aboveΒ and changes inΒ theΒ value of investments quoted on regulated markets,Β theΒ Board is not aware of anyΒ material events during the period from 1Β SeptemberΒ toΒ 30Β NovemberΒ 2008,Β or in the period from 1Β DecemberΒ 2008Β to the date of this announcement, which would haveΒ hadΒ a material impact on the financial position of the Company.

Issued on behalf of the Board

Aberdeen Asset ManagementΒ PLC, Secretary

7Β January 2009

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
IMSUUUQCGUPBGAM
Date   Source Headline
26th Jun 20269:30 amRNSIssue of Equity
23rd Jun 20264:06 pmRNSAudited NAV - Dividend Investment Scheme
2nd Jun 20264:19 pmRNSAnnual Financial Report
1st May 20263:20 pmRNSTransaction in Own Shares
30th Apr 20265:09 pmRNSTransaction in Own Shares
30th Apr 202610:51 amRNSAdmission of Further Securities to Trading
29th Apr 202612:23 pmRNSIssue of Equity
27th Apr 20263:29 pmRNSUnaudited Net Asset Value and Dividend Declaration
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:17 amRNSAdmission of Further Securities to Trading
14th Apr 202611:06 amRNSIssue of Equity
8th Apr 20269:27 amRNSAdmission of Further Securities to Trading
25th Mar 202610:49 amRNSAdmission of Further Securities to Trading
24th Mar 202612:08 pmRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
29th Jan 20264:54 pmRNSTransaction in Own Shares
21st Jan 202611:01 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:39 amRNSIssue of Equity
15th Jan 202610:27 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 202610:26 amRNSDirector/PDMR Shareholding
15th Jan 20269:50 amRNSIssue of Equity
14th Jan 20262:33 pmRNSUnaudited NAV - Dividend Investment Scheme
4th Dec 202510:35 amRNSUnaudited NAV and Second Interim Dividend
13th Nov 20253:39 pmRNSResult of General Meeting
29th Oct 20257:00 amRNSHalf-year Report
16th Oct 20254:43 pmRNSTransaction in Own Shares
2nd Oct 20254:42 pmRNSPublication of a Prospectus
15th Sep 20251:06 pmRNSNet Asset Value(s)
29th Aug 20257:00 amRNSIssue of Equity
20th Aug 20252:12 pmRNSStatement re Dividend Investment Scheme
23rd Jul 20254:33 pmRNSTransaction in Own Shares
18th Jul 202510:08 amRNSIssue of Equity - Dividend Investment Scheme
16th Jul 20257:08 amRNSStatement re Offer for Subscription
11th Jul 20253:56 pmRNSStatement re Dividend Investment Scheme
11th Jul 20252:58 pmRNSStatement re Unaudited NAV and Interim Dividend
10th Jul 20252:32 pmRNSResult of AGM
28th May 20254:18 pmRNSAnnual Financial Report
7th May 20254:35 pmRNSTransaction in Own Shares
6th May 202511:51 amRNSIssue of Equity
25th Apr 20254:19 pmRNSUnaudited NAV and Proposed Final Dividend
17th Apr 202512:56 pmRNSPublication of Suppl.Prospcts
7th Apr 20257:00 amRNSIssue of Equity - Replacement
4th Apr 20256:15 pmRNSIssue of Equity
1st Apr 202512:59 pmRNSStatement re Offers for Subscription - Closed
27th Mar 20251:02 pmRNSIssue of Equity
27th Mar 202510:25 amRNSUpdate re: Offers for Subscription
24th Mar 20253:23 pmRNSUnaudited Net Asset Value
29th Jan 20254:35 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.